Nanoviricides, INC 8-K filings

NanoViricides, Inc. announced the pricing of a registered direct offering expected to raise approximately $3.8 million before expenses.

NanoViricides, Inc. has entered into an At Market Issuance Sales Agreement with D. Boral Capital LLC to offer and sell shares of its common stock.

NanoViricides, Inc. announced that its drug candidates, NV-387 and NV-387 with encapsulated Remdesivir, are expected to be effective against the current Ebola virus strain in the Democratic Republic of Congo.

NanoViricides, Inc. has successfully closed a registered direct offering, raising approximately $2 million through the sale of common stock and warrants.

NanoViricides, Inc. stockholders re-elected Anil Diwan as a Class I Director, approved executive compensation, and ratified EisnerAmper, LLP as their independent auditor at the 2025 Annual Meeting.

NanoViricides, Inc. has successfully closed a $6 million registered direct offering and concurrent private placement to fund working capital and general corporate purposes.

NanoViricides, Inc. extended employment agreements for its President and CFO, while also increasing and extending a $3 million line of credit from its President at a 12% interest rate, secured by company assets.

NanoViricides successfully held its 2024 Annual Meeting, re-electing three directors and ratifying its independent accounting firm for the upcoming fiscal year.

NanoViricides has extended the employment agreements for its President, Anil Diwan, and Chief Financial Officer, Meeta Vyas, through June 30, 2025.

NanoViricides, Inc. has updated its at-the-market offering agreement, replacing B. Riley Securities with EF Hutton LLC as the sole sales agent for potential stock sales up to $50 million.

NanoViricides has amended its license agreement with TheraCour Pharma, extended its line of credit with its CEO, and suspended a required advance payment to TheraCour.

NanoViricides, Inc. held its 2023 Annual Meeting of Stockholders, where key proposals including the re-election of a director and approval of executive compensation were passed.